Background

Overview

My main research activities are spread across two areas (drug discovery and radical enzymes ) and two spin-out companies (NewChem Technologies and BiBerChem Research, based in the Biosphere on the Newcastle Helix site) for which I am scientific director.

I am a co-inventor of the drug rucaparib (Rubraca), approved by the FDA and EMA for treatment of BRCA-mutant ovarian cancer and available via the NHS.

I have supervised/co-supervised 100 PhD students successfully to graduation, as well as the research projects of ca. 100 master's/ERASMUS students.

Qualifications

BSc and PhD (University of Manchester); honorary DPhil (University of Stockholm).

Research Publications

Total Number of Publications: 468 including 348 research papers, 40 reviews, 10 commentaries and 4 edited books (164 research papers and 15 reviews since 2000) [data from Web of Science]. Note: published abstracts are excluded.

Total Number of Patents: 60 listed in espacenet.com mainly for drug development projects (cancer treatment, essential thrombocythemia, Alzheimer’s disease, severe pain, gastrointestinal disturbances).

Recent Awards

2019 Robert Robinson Award of the Royal Society of Chemistry, for contributions to biochemistry, microbiology and medicine.

2010 Co-winner of the 1^st Cancer Research UK ‘Translational Research Prize’, for inventing and developing potent inhibitors of polyADP-ribose polymerase-1 leading to the drug rucaparib/Rubraca.

2005 Doctor of Philosophy cum lauda (University of Stockholm, 2005) [awarded alongside J Saramago, winner of Nobel Prize for Literature 1998].

Extramural Interests

Walking/running (raising money for charities); cycling; improving animal welfare; cinema (especially Coen brothers).

Research

Overview

Although I was trained as a synthetic organic chemist, working under Professor A Eschenmoser on the total synthesis of vitamin B12, my main interests today are the application of synthesis to the solution of problems in biology and medicine. This can mean the synthesis of isotopically labelled substrates for studying an enzyme mechanism or the synthesis of potential drugs for treating cancer. Synthesis is therefore central to all my studies and I am always looking for new ways to expedite reactions and improve methodology. Mechanistic studies are also a major focus, especially the catalytic reactions of radical enzymes. I collaborate widely in order to maximise the ability to solve interdisciplinary problems. At Newcastle, besides my research studying radical enzymes, I have worked within a team of scientists developing new drugs against cancer targets. I was co-founder of this group in 1990 (with A H Calvert and D R Newell). In 2010, we were awarded the first translational research prize from Cancer Research UK for our pioneering work on inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase. I also have had many international collaborations, involving scientists in Australia, Germany, Italy, Japan, Sweden and Switzerland. My co-workers have often spent time in collaborator’s laboratories and there have been frequent visitors from abroad. My group has always been multinational with students or postdocs from e.g. China, France, Germany, India, Iran, Italy, Poland and Spain, as well as the UK. I have supervised/co-supervised more than 100 research students, all of whom obtained the PhD degree. My research has been funded by a variety of sources including the European Commission, German Research Foundation (DFG), UK Research Councils, Cancer Research UK and the pharmaceutical industry.

In addition to my academic research, I am scientific director of the spin-out companies NewChem Technologies (founded 2002) and BiBerChem Research (2017), which are housed in the Biosphere, Newcastle Helix site. NewChem has 23 employees currently, many of whom are former Newcastle chemistry graduates, and works in collaboration with pharmaceutical and academic partners to develop new therapeutic agents.

RESEARCH AREAS

 Application of chemical synthesis and mechanistic studies to the solution of problems in biology and medicine: 

Drug Discovery.- rational design of new anticancer agents based on the molecular pathology of cancer; targets include poly(ADP-ribose) polymerases, DNA-dependent protein kinase, cyclin dependent kinases and the MDM2/p53 protein-protein interaction [collaboration with colleagues in Chemistry [R J Griffin (deceased), M J Waring et al] and Newcastle Medical School (A H Calvert, D R Newell et al)]. Interdisciplinary research at Newcastle University discovered the first potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase 1 (PARP-1) through medicinal chemistry (directed by myself and R J Griffin), cancer pharmacology and preclinical work leading to first-in-human clinical studies. This research led to the development of the drug rucaparib (trade name Rubraca), which was granted approval by the US Food & Drug Administration (2016) and European Medicines Agency (2018) for the treatment of BRCA mutant ovarian cancer and is now available via the NHS.

The importance of the Newcastle team’s contribution was recognised by the award (2010) of the first Cancer Research UK Translational Cancer Research prize to Golding and Griffin (School of Chemistry) with A H Calvert, N J Curtin, B Durkacz, D R Newell (Northern Institute for Cancer Research). This research was also the basis of School of Chemistry Impact Cases for the 2014 and 2021 Research Excellence Framework (REF) achieving a 4* rating in both.

Enzyme Mechanisms.- especially unusual or ‘impossible’ reactions including those for which radicals are intermediates, e.g. coenzyme B₁₂-dependent reactions; anaerobic functionalisation of hydrocarbons and prebiotic enzyme-like processes [partly in collaboration with: W Buckel, H Heider (Marburg); R Rabus, H Wilkes (Oldenburg); C Chatgiliagolu (Bologna)].

Synthetic Organic Chemistry.- synthesis of biologically active molecules including specifically labelled compounds; development of new methodology including protecting groups; use of 2,2,2-trifluoroethanol in synthesis; bifurcating hydrogen bonding for catalysing epoxide reactions with amine nucleophiles.

Other Research.- Molecular toxicology (atmospheric pollutants, e.g. benzene), prebiotic chemistry, hydrogen production (clean energy), carbon dioxide sequestration; environmental chemistry.

Publications

Total Number of Publications: 468 including 348 research papers, 60 patents, 40 reviews, 10 commentaries and 4 edited books (164 research papers, 57 patents, and 15 reviews since 2000) [Web of Science and espacenet.com data excluding published abstracts].

10 Highly Cited Publications since 2000

1.     White AW, Griffin RJ, Golding BT et al, Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP), J Med Chem, 2000, 43, 4084-4097 [264 citations]

2.     Arris CE, Golding BT, Griffin RJ et al, Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles, J Med Chem, 2000, 43, 2797-2804 [200 citations]

3.     Smith DM, Golding BT, Radom L, Understanding the mechanism of B₁₂-dependent diol dehydratase: A synergistic retro-push-pull proposal, J Am Chem Soc, 2001, 123, 1664-1675 [90 citations]

4.     Davies TG, Golding BT, Griffin RJ et al, Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor, Nat Chem Biol, 2002, 9, 745-749 [196 citations]

5.     Leahy JJJ, Golding BT, Griffin RJ et al, Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries, Bioorg Med Chem Lett, 2004, 14, 6083-6087 [307 citations]

6.     Buckel W, Golding BT, Radical enzymes in anaerobes. Annu Rev Microbiol. 2006, 60, 27-49 [139 citations]

7.     Wang X, Golding BT, Scott, K et al, A polytetrafluoroethylene-quaternary 1,4-diazabicyclo-[2.2.2]-octane polysulfone composite membrane for alkaline anion exchange membrane fuel cells, Int J Hydrogen Energy, 2011, 36, 10022-10026 [71 citations]

8.     Hardcastle IR, Golding BT, Griffin RJ et al, Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency, J Med Chem, 2011, 54, 1233-1243[125 citations]

9.     Jarling R, Golding BT, Wilkes H et al, Stereochemical investigations reveal the mechanism of the bacterial activation of n-alkanes without oxygen, Angew Chem Intl Edn, 2012, 51, 1334-1338 [53 citations]

10.  Kimes NE, Callaghan AV, Golding BT et al, Metagenomic analysis and metabolite profiling of deep-sea sediments from the Gulf of Mexico following the Deepwater Horizon oil spill, Frontiers Microbiol, 2013, 4, Article no 50 [187 citations]

--------------------------------------------------------------------------------

Teaching

Overview

I have delivered around 2000 lectures during my academic career covering most areas of orgnaic chemistry (including biological, medicinal and synthetic chemistry).

Recent Courses

Structural Chemistry - Mass Spectrometry

Bioactive Natural Products

Chemical Toxicology and Drug Metabolism

Chemical Biology

Publications

• Articles

  • Watson WP, Munter T, Golding BT. The effect of vitamin B12 on DNA adduction by styrene oxide, a genotoxic xenobiotic. Chemico-Biological Interactions 2023, 382, 110591.
  • Miller DC, Reuillon T, Molyneux L, Blackburn T, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hardcastle I, Harnor SJ, Heptinstall A, Lochhead P, Martin MP, Martin NC, Myers S, Newell DR, Noble RA, Phillips N, Rigoreau L, Thomas H, Tucker JA, Wang L-Z, Waring MJ, Wong A-C, Wedge SR, Noble MEM, Cano C. Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry 2022, 65(9), 6513-6540.
  • Golding BT, Abelairas-Edesa M, Tilbury RD, Wilson JP, Zhang D, Henderson AP, Bleasdale C, Clegg W, Watson WP. Influence of the methyl group in isoprene epoxides on reactivity compared to butadiene epoxides: Biological significance. Chemico-Biological Interactions 2022, 361, 109949.
  • Uguen M, Davison G, Sprenger LJ, Hunter JH, Martin MP, Turberville S, Watt JE, Golding BT, Noble MEM, Stewart HL, Waring MJ. Build–Couple–Transform: A paradigm for lead-like library synthesis with scaffold diversity. Journal of Medicinal Chemistry 2022, 65(16), 11322-11339.
  • Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscome E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, Carbain B, Castro J, Cons B, Cully SJ, St Denis J, Endicott JA, Fazal L, Golding BT, Griffin RJ, Haggerty K, Harnor S, Hearn K, Hobson S, Holvey RS, Howard S, Jennings C, Johnson CN, Lunec J, Miller DC, Newell DR, Noble MEM, Reeks J, Revill CH, Riedinger C, Tamanini E, Thomas H, Thompson NT, Vinkovic M, Wedge SR, Williams PA, Wilsher N, Zhang B, Zhao Y. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction. Journal of Medicinal Chemistry 2021, 64(7), 4071-4088.
  • Mitschke N, Erucar G, Fsadni MH, Roberts AR, Sadeghi MM, Golding BT, Christoffers J, Wilkes H. Enantiopure 2,9-Dideuterodecane – Preparation and Proof of Enantiopurity. European Journal of Organic Chemistry 2021, 2021(27), 3854-3863.
  • Drozdowska M, Tromans J, Zhang B, Jarling R, Wilkes H, Golding BT. Defining Pathways of Anaerobic Alkane Oxidation: Synthesis of Enantiomers of 4-Methylalkanoic Acids and (2-Methylalkyl)malonic Acids. ChemistrySelect 2021, 6(16), 3976-3981.
  • Picazo EMH, Heptinstall AB, Wilson DM, Cano C, Golding BT, Waring MJ. Cyclisations and fragmentations in the alkylation of 6-chloro-5-hydroxy-4-aminopyrimidines with aminoalkyl chlorides. Journal of Heterocyclic Chemistry 2021, 58(4), 947-951.
  • Al-Khawaldeh I, Aldred GG, Alyassiri M, Basmadjian C, Bordoni C, Harnor SJ, Heptinstall AB, Hobson SJ, Jennings CE, Khalifa S, Lebraud H, Miller DC, Shrives HJ, de Souza JV, Stewart HL, Temple M, Totobenazara J, Tucker JA, Tudhope SJ, Wang LZ, Bronowska AK, Cano C, Endicott JA, Golding BT, Hardcastle IR, Hickson I, Wedge SR, Willmore E, Noble MEM, Waring MJ. An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK). Journal of Medicinal Chemistry 2021, 64(14), 10001-10018.
  • Al-Sheikh A, Begum M, Zhang B, Lewis RA, Allenby NEE, Waddell PG, Golding BT. Molecular Diversity via Tetrasubstituted Alkenes Containing a Barbiturate Motif: Synthesis and Biological Activity. Molecules (Basel, Switzerland) 2020, 25(24), 5868.
  • Matheson CJ, Coxon CR, Bayliss R, Boxall K, Carbain B, Fry AM, Hardcastle IR, Harnor SJ, Mas-Droux C, Newell DR, Richards MW, Sivaprakasam M, Turner D, Griffin RJ, Golding BT, Cano C. 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase. RSC Medicinal Chemistry 2020, 11(6), 707-731.
  • Newland MJ, Rea GJ, Thuner LP, Henderson AP, Golding BT, Rickard AR, Barnes I, Wenger J. Photochemistry of 2-butenedial and 4-oxo-2-pentenal under atmospheric boundary layer conditions. Physical Chemistry Chemical Physics 2019, 21(3), 1160-1171.
  • Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang L-Z, Wong A-C, Noble MEM, Wedge SR, Cano C. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. European Journal of Medicinal Chemistry 2019, 178, 530-543.
  • Golding BT, Waring MJ. The consequences of ‘Brexit’ for drug discovery and development, and the regulatory implications. Expert Opinion on Drug Discovery 2018, 13(7), 583-585.
  • Miller DC, Martin MP, Adhikari S, Brennan A, Endicott JA, Golding BT, Hardcastle IR, Heptinstall A, Hobson S, Jennings C, Molyneux L, Ng Y, Wedge SR, Noble MEM, Cano C. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Organic and Biomolecular Chemistry 2018, 16(11), 1843-1850.
  • Barata-Vallejo S, Ferreri C, Golding BT, Chatgilialoglu C. Hydrogen Sulfide: A Reagent for pH-Driven Bioinspired 1,2-Diol Mono-deoxygenation and Carbonyl Reduction in Water. Organic Letters 2018, 20(14), 4290-4294.
  • Espiritu R, Golding BT, Scott K, Mamlouk M. Degradation of radiation grafted anion exchange membranes tethered with different amine functional groups via removal of vinylbenzyl trimethylammonium hydroxide. Journal of Power Sources 2018, 375, 373-386.
  • Coxon RC, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget 2017, 8, 19089-19124.
  • Coxon C, Anscombe E, Harnor S, Martin M, Carbain B, Golding B, Hardcastle I, Harlow L, Korolchuk S, Matheson C, Newell D, Noble M, Sivaprakasam M, Tudhope SJ, Turner D, Wang L, Wedge SR, Wong C, Griffin R, Endicott J, Cano C. Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry 2017, 60, 1746-1767.
  • Mullaney JC, Medcraft C, Tew DP, Lewis-Borrell L, Golding BT, Walker NR, Legon AC. Cooperative Hydrogen Bonds Form a Pseudocycle Stabilizing an Isolated Complex of Isocyanic Acid with Urea. Physical Chemistry Chemical Physics 2017, 19, 25080-25085.
  • Cortese D, Konstantin C, Guglielmo S, Wang LZ, Golding BT, Cano C, Fruttero R. Synthesis and Biological Evaluation of N²-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors. ChemMedChem 2016, 11(6), 1705-1708.
  • Wang X, Wang Y, Golding BT, Yu EH, Scott K. Preparation of a Chemically Stable Polysulfone-based Anion Exchange Membrane Using DABCO as the Quaternization Agent. Chemical Engineering Transactions 2016, 51, 121-126.
  • Tommasino C, Gambardella L, Buoncervello M, Griffin RJ, Golding BT, Alberton M, Macchia D, Spada M, Cerbelli B, d'Amati G, Malorni W, Gabriele L, Giammarioli AM. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study. Journal of Experimental & Clinical Cancer Research 2016, 35, 137.
  • Myers SM, Bawn RH, Bisset LC, Blackburn TJ, Cottyn B, Molyneux L, Wong AC, Cano C, Clegg W, Harrington RW, Leung H, Rigoreau L, Vidot S, Golding BT, Griffin RJ, Hammonds T, Newell DR, Hardcastle IR. High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors. ACS Combinatorial Science 2016, 18(8), 444-455.
  • Seyhan D, Friedrich P, Szaleniec M, Hilberg M, Buckel W, Golding BT, Heider J. Elucidating the stereochemistry of enzymatic benzylsuccinate synthesis with chirally labeled toluene. Angewandte Chemie International Edition 2016, 55(38), 11664-11667.
  • Reuillon T, Alhasan SF, Beale GS, Bertoli A, Brennan A, Cano C, Reeves HL, Newell DR, Golding BT, Miller DC, Griffin RJ. Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. Chemical Science 2016, 7(4), 2821-2826.
  • Zaytsev AV, Pickles JE, Harnor SJ, Henderson AP, Alyasiri M, Waddell PG, Cano C, Griffin RJ, Golding BT. Concise syntheses of bridged morpholines. RSC Advances 2016, 6(59), 53955-53957.
  • Beale G, Haagensen E, Thomas H, Wang LZ, Revill C, Payne S, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer. British Journal of Cancer 2016, 115, 682-690.
  • Rabus R, Boll M, Heider J, Meckenstock RU, Buckel W, Einsle O, Ermler U, Golding BT, Gunsalus RP, Kroneck PMH, Kruger M, Lueders T, Martins BM, Musat F, Richnow HH, Schink B, Seifert J, Szaleniec M, Treude T, Ullmann GM, Vogt C, von Bergen M, Wilkes H. Anaerobic Microbial Degradation of Hydrocarbons: From Enzymatic Reactions to the Environment. Journal of Molecular Microbiology and Biotechnology 2016, 26(1-3), 5-28.
  • Rabus R, Boll M, Golding B, Wilkes H. Anaerobic Degradation of p-Alkylated Benzoates and Toluenes. Journal of Molecular Microbiology and Biotechnology 2016, 26(1-3), 63-75.
  • Mitcheson DF, Bottrill AR, Carr K, Coxon CR, Cano C, Golding BT, Griffin RJ, Fry AM, Doerig C, Bayliss R, Tobin AB. A new tool for the chemical genetic investigation of the Plasmodium falciparum Pfnek-2 NIMA-related kinase. Malaria Journal 2016, 15, 535.
  • Jarling R, Kuhner S, Janke EB, Gruner A, Drozdowska M, Golding BT, Rabus R, Wilkes H. Versatile transformations of hydrocarbons in anaerobic bacteria: substrate ranges and regio- and stereo-chemistry of activation reactions. Frontiers in Microbiology 2015, 6, 880.
  • Shouksmith AE, Evans LE, Tweddle DA, Miller DC, Willmore E, Newell DR, Golding BT, Griffin RJ. Synthesis and Activity of Putative Small-​Molecule Inhibitors of the F-​Box Protein SKP2. Australian Journal of Chemistry 2015, 68(4), 660-679.
  • Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach. Chemical Biology and Drug Discovery 2015, 86(2), 180-189.
  • Miller DC, Carbain B, Beale GS, Alhasan SF, Reeves HL, Baisch U, Newell DR, Golding BT, Griffin RJ. Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases. Organic & Biomolecular Chemistry 2015, 13(18), 5279-5284.
  • Dragicevic I, Baric D, Kovacevic B, Golding BT, Smith DM. Non-enzymatic Ribonucleotide Reduction in the Prebiotic Context. Chemistry: A European Journal 2015, 21(16), 6132-6143.
  • Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble MEM, Wedge SR, Endicott JA, Griffin RJ. Identification and characterization of an irreversible inhibitor of CDK2. Chemistry & Biology 2015, 22(9), 1159-1164.
  • Yamada Y, Wehrli P, Miljkovic D, Wild H-J, Buhler N, Gotschi E, Golding B, Loliger P, Gleason J, Place B, Ellis L, Hunkeler W, Schneider P, Fuhrer W, Nordmann R, Srinivasachar K, Keese R, Muller K, Neier R, Eschenmoser A. Corrin Synthesis via A→D Ring Closure. The Construction of A/D-Secocorrin Chromophore Systems by the ‘Sulfide Contraction’ Method and the Photochemical A/B-Secocorrin→Corrin Cycloisomerization. Helvetica Chimica Acta 2015, 98(11-12), 1921-2054.
  • Carbain B, Coxon CR, Lebraud H, Elliott KJ, Matheson CJ, Meschini E, Roberts AR, Turner DM, Wong C, Cano C, Griffin RJ, Hardcastle IR, Golding BT. Trifluoroacetic Acid in 2,2,2-Trifluoroethanol Facilitates S_NAr Reactions of Heterocycles with Arylamines. Chemistry: A European Journal 2014, 20(8), 2311-2317.
  • Harnor SJ, Rennison T, Galler M, Cano C, Griffin RJ, Newell DR, Golding BT. Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [¹⁸F]FLT. MedChemComm 2014, 5(7), 984-988.
  • Lebraud H, Coxon CR, Archard VS, Bawn CM, Carbain B, Matheson CJ, Turner DM, Cano C, Griffin RJ, Hardcastle IR, Baisch U, Harrington RW, Golding BT. Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles. Organic & Biomolecular Chemistry 2014, 12, 141-148.
  • Strijkstra A, Trautwein K, Jarling R, Wohlbrand L, Dorries M, Reinhardt R, Drozdowska M, Golding BT, Wilkes H, Rabus R. Anaerobic Activation of p-Cymene in Denitrifying Betaproteobacteria: Methyl Group Hydroxylation versus Addition to Fumarate. Applied and Environmental Microbiology 2014, 80(24), 7592-7603.
  • Motwani HV, Shimakoshi H, Golding BT, Tornqvist M, Hisaeda Y. Alkylcobyrinate from sucralose and mechanistic aspects of its Co-C bond cleavage. Tetrahedron Letters 2014, 55(16), 2667-2670.
  • Carbain B, Paterson DJ, Anscombe E, Campbell AJ, Cano C, Echalier A, Endicott JA, Golding BT, Haggerty K, Hardcastle IR, Jewsbury PJ, Newell DR, Noble MEM, Roche C, Wang LZ, Griffin RJ. 8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode. Journal of Medicinal Chemistry 2014, 57(1), 56-70.
  • Lebraud H, Cano C, Carbain B, Hardcastle IR, Harrington RW, Griffin RJ, Golding BT. Trifluoroethanol solvent facilitates selective N-7 methylation of purines. Organic & Biomolecular Chemistry 2013, 11(11), 1874-1878.
  • Kimes NE, Callaghan AV, Aktas DF, Smith WL, Sunner J, Golding BT, Drozdowska M, Hazen TC, Suflita JM, Morris PJ. Metagenomic analysis and metabolite profiling of deep-sea sediments from the Gulf of Mexico following the Deepwater Horizon oil spill. Frontiers in Microbiology 2013, 4, 50.
  • Blackburn TJ, Ahmed S, Coxon CR, Liu JF, Lu XH, Golding BT, Griffin RJ, Hutton C, Newell DR, Ojo S, Watson AF, Zaytzev A, Zhao Y, Lunec J, Hardcastle IR. Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions. MedChemComm 2013, 4(9), 1297-1304.
  • Eberlein C, Johannes J, Mouttaki H, Sadeghi M, Golding BT, Boll M, Meckenstock RU. ATP-dependent/-independent enzymatic ring reductions involved in the anaerobic catabolism of naphthalene. Environmental Microbiology 2013, 15(6), 1832-1841.
  • Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GCM, Thommes P, Ting A, Griffin RJ. 1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity. Journal of Medicinal Chemistry 2013, 56(16), 6386-6401.
  • Scott RB, Downey KM, Healy KP, Henderson AP, Robinson CL, Clegg W, Harrington RW, Franklin R, Golding BT. Synthesis and stability of 3-hydroxyanagrelide, a biologically potent metabolite of anagrelide. Heterocycles 2012, 86(2), 1637-1646.
  • Jarling R, Sadeghi M, Drozdowska M, Lahme S, Buckel W, Rabus R, Widdel F, Golding BT, Wilkes H. Stereochemical Investigations Reveal the Mechanism of the Bacterial Activation of n-Alkanes without Oxygen. Angewandte Chemie: International Edition 2012, 51(6), 1334-1338.
  • Jiang D, Barata-Vallejo S, Golding BT, Ferreri C, Chatgilialoglu C. Revisiting the reaction of hydroxyl radicals with vicinal diols in water. Organic & Biomolecular Chemistry 2012, 10(5), 1102-1107.
  • Clapham KM, Rennison T, Jones G, Craven F, Bardos J, Golding BT, Griffin RJ, Haggerty K, Hardcastle IR, Thommes P, Ting A, Cano C. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives. Organic & Biomolecular Chemistry 2012, 10(33), 6747-6757.
  • Zhang ZL, Tian C, Zhou SX, Wang W, Guo Y, Xia J, Liu ZM, Wang BA, Wang XW, Golding BT, Griffin RJ, Du YS, Liu JY. Mechanism-based design, synthesis and biological studies of N-5-substituted tetrahydrofolate analogs as inhibitors of cobalamin-dependent methionine synthase and potential anticancer agents. European Journal of Medicinal Chemistry 2012, 58, 228-236.
  • Buckel W, Friedrich P, Golding BT. Hydrogen Bonds Guide the Short-Lived 5 '-Deoxyadenosyl Radical to the Place of Action. Angewandte Chemie: International Edition 2012, 51(40), 9974-9976.
  • Friedrich P, Baisch U, Harrington RW, Lyatuu F, Zhou K, Zelder F, McFarlane W, Buckel W, Golding BT. Experimental Study of Hydrogen Bonding Potentially Stabilizing the 5'-Deoxyadenosyl Radical from Coenzyme B12. Chemistry: A European Journal 2012, 18(50), 16114-16122.
  • Reuillon T, Bertoli A, Griffin RJ, Miller DC, Golding BT. Efficacious N-protection of O-aryl sulfamates with 2,4-dimethoxybenzyl groups. Organic & Biomolecular Chemistry 2012, 10(37), 7610-7617.
  • Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L, Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson CN. Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS One 2012, 7(10), e45539.
  • Rodriguez SA, Clapham KM, Barrett L, Cano C, Desage ME, Griffin RJ, Hardcastle IR, Payne SL, Rennison T, Richardson C, Golding BT. Versatile Synthesis of Functionalised Dibenzothiophenes via Suzuki Coupling and Microwave-assisted Ring Closure. Organic & Biomolecular Chemistry 2011, 9(17), 6066-6074.
  • Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer 2011, 47(13), 2052-2059.
  • Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein. Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
  • Bali S, Lawrence AD, Lobo SA, Saraiva LM, Golding BT, Palmer DJ, Howard MJ, Ferguson SJ, Warren MJ. Molecular hijacking of siroheme for the synthesis of heme and d(1) heme. Proceedings of the National Academy of Sciences 2011, 108(45), 18260-18265.
  • Watson AF, Liu JF, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu XH, McDonnell JM, Newell DR, Noble MEM, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR. MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones. Bioorganic & Medicinal Chemistry Letters 2011, 21(19), 5916-5919.
  • Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J. Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency. Journal of Medicinal Chemistry 2011, 54(5), 1233-1243.
  • Begemann P, Boysen G, Georgieva NI, Sangaiah R, Koshlap KM, Koc H, Zhang DP, Golding BT, Gold A, Swenberg JA. Identification and Characterization of 2 '-Deoxyadenosine Adducts Formed by Isoprene Monoepoxides in Vitro. Chemical Research in Toxicology 2011, 24(7), 1048-1061.
  • Clapham KM, Bardos J, Finlay R, Golding BT, Griffen EJ, Griffin RJ, Hardcastle IR, Menear KA, Ting A, Turner P, Young GL, Cano C. DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain. Bioorganic & Medicinal Chemistry Letters 2011, 21(3), 966-970.
  • Motwani HV, Qiu SR, Golding BT, Kylin H, Tornqvist M. Cob(I)alamin reacts with sucralose to afford an alkylcobalamin: Relevance to in vivo cobalamin and sucralose interaction. Food and Chemical Toxicology 2011, 49(4), 750-757.
  • Wong C, Griffin RJ, Hardcastle IR, Northen JS, Wang LZ, Golding BT. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated S_N2 reactivity of 2,2,2-trifluoroethoxysulfonates. Organic & Biomolecular Chemistry 2010, 8(10), 2457-2464.
  • Marchetti F, Cano C, Curtin NJ, Golding BT, Griffin RJ, Haggerty K, Newell DR, Parsons RJ, Payne SL, Wang LZ, Hardcastle IR. Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors. Organic & Biomolecular Chemistry 2010, 8(10), 2397-2407.
  • Golding BT, Barnes ML, Bleasdale C, Henderson AP, Jiang D, Li X, Mutlu E, Petty HJ, Sadeghi MM. Modeling the formation and reactions of benzene metabolites. Chemico-Biological Interactions 2010, 184(1-2), 196-200.
  • Payne SL, Rodriguez-Aristegui S, Bardos J, Cano C, Golding BT, Hardcastle IR, Peacock M, Parveen N, Griffin RJ. Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors. Bioorganic & Medicinal Chemistry Letters 2010, 20(12), 3649-3653.
  • Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ. DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry 2010, 53(24), 8498-8507.
  • Cano C, Golding BT, Haggerty K, Hardcastle IR, Peacock M, Griffin RJ. Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK). Organic & Biomolecular Chemistry 2010, 8(8), 1922-1928.
  • Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics 2009, 8(7), 1828-1837.
  • Velarde M, Macieira S, Hilberg M, Broker G, Tu SM, Golding BT, Pierik AJ, Buckel W, Messerschmidt A. Crystal Structure and Putative Mechanism of 3-Methylitaconate-Delta-isomerase from Eubacterium barkeri. Journal of Molecular Biology 2009, 391(3), 609-620.
  • Motwani HV, Fred C, Hagolund J, Golding BT, Tornqvist M. Cob(I)alamin for Trapping Butadiene Epoxides in Metabolism with Rat S9 and for Determining Associated Kinetic Parameters. Chemical Research in Toxicology 2009, 22(9), 1509-1516.
  • Suarez D, Laval G, Tu SM, Jiang D, Robinson CL, Scott R, Golding BT. Benzylic Brominations with N-Bromosuccinimide in (Trifluoromethyl)benzene. Synthesis 2009, (11), 1807-1810.
  • Thiele B, Rieder O, Golding BT, Müller M, Boll M. Mechanism of Enzymatic Birch Reduction: Stereochemical Course and Exchange Reactions of Benzoyl-CoA Reductase. Journal of the American Chemical Society 2008, 130(43), 14050-14051.
  • Pierik AJ, Graf T, Pemberton L, Golding BT, Retey J. But-3-ene-1,2-diol: A Mechanism-Based Active Site Inhibitor for Coenzyme B-12-Dependent Glycerol Dehydratase. ChemBioChem 2008, 9(14), 2268-2275.
  • Bauer G, Chatgilialoglu C, Gebicki JL, Gebicka L, Gescheidt G, Golding BT, Goldstein S, Kaizer J, Merenyi G, Speier G, Wardman P. Biologically relevant small radicals. Chimia 2008, 62(9), 704-712.
  • Riedinger C, Endicott JA, Kemp SJ, Smyth LA, Watson A, Valeur E, Golding BT, Griffin RJ, Hardcastle IR, Noble ME, McDonnell JM. Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction. Journal of the American Chemical Society 2008, 130(47), 16038-16044.
  • Murr M, Cano C, Golding BT, Hardcastle IR, Hummersome M, Frigerio M, Curtin NJ, Menear K, Richardson C, Smith G, Griffin R. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic and Medicinal Chemistry Letters 2008, 18(17), 4885-4890.
  • Munter T, Cottrell L, Ghai R, Golding BT, Watson WP. The metabolism and molecular toxicology of chloroprene. Chemico-Biological Interactions 2007, 166(1-3), 323-331.
  • Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR, Mesguiche V, Newell DR, Noble MEM, Parsons RJ, Pratt DJ, Wang L, Hardcastle IR. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic and Biomolecular Chemistry 2007, 5(10), 1577-1585.
  • Barbeau OR, Cano-Soumillac C, Griffin RJ, Hardcastle IR, Smith GCM, Richardson C, Clegg W, Harrington RW, Golding BT. Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase. Organic & Biomolecular Chemistry 2007, 5(16), 2670-2677.
  • Hollick J, Rigoreau L, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone M, Menear K, Martin N, Matthews I, Newell DR, Ord R, Richardson C, Smith G, Griffin RJ. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. Journal of Medicinal Chemistry 2007, 50(8), 1958-1972.
  • Butler P, Golding BT, Laval G, Loghmani-Khouzani H, Ranjbar-Karimi R, Sadeghi MM. Fluorination and chlorination of nitroalkyl groups. Tetrahedron 2007, 63(45), 11160-11166.
  • Seeberger S, Griffin RJ, Hardcastle IR, Golding BT. A new strategy for the synthesis of taurine derivatives using the 'safety-catch' principle for the protection of sulfonic acids. Organic & Biomolecular Chemistry 2007, 5(1), 132-138.
  • Buckel W, Kratky C, Golding BT. Stabilisation of methylene radicals by Cob(II)alamin in coenzyme B₁₂ dependent mutases. Chemistry - A European Journal 2006, 12(2), 352-362.
  • Sadeghi MM, Loghmani-Khouzani H, Ranjbar-Karimi R, Golding BT. Sonochemical fluorination of heterocyclic nitro compounds with Selectfluor™ (F-TEDA-BF4). Tetrahedron Letters 2006, 47(14), 2455-2457.
  • Hardcastle, I.R., Ahmed, S., Atkins, H., Farnie, G., Golding, B.T., Griffin, R.J., Guyenne, S., Hutton,C., Källblad, P., Kemp, S., Kitching, M.S., Newell, D.R., Norbedo, S., Northen, J.S., Reid, R.J., Saravanan, K., Willems, H., Lunec, J. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. Journal of Medicinal Chemistry 2006, 49(21), 6209-6221.
  • Griffin RJ, Henderson A, Curtin NJ, Echalier A, Endicott J, Hardcastle IR, Newell DR, Noble M, Wang L, Golding BT. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. Journal of the American Chemical Society 2006, 128(18), 6012-6013.
  • Buckel W, Pierik AJ, Plett S, Alhapel A, Suarez D, Tu S-M, Golding BT. Mechanism-based inactivation of coenzyme B12-dependent 2-methyleneglutarate mutase by (Z)-glutaconate and buta-1,3-diene-2,3- dicarboxylate. European Journal of Inorganic Chemistry 2006, (18), 3622-3626.
  • Aristegui SR, El-Murr MD, Golding BT, Griffin RJ, Hardcastle IR. Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors. Organic Letters 2006, 8(26), 5927-5929.
  • Sandala GM, Smith DM, Coote ML, Golding BT, Radom L. Insights into the hydrogen-abstraction reactions of diol dehydratase: Relevance to the catalytic mechanism and suicide inactivation. Journal of the American Chemical Society 2006, 128(10), 3433-3444.
  • Naser U, Pierik AJ, Scott R, Cinkaya I, Buckel W, Golding BT. Synthesis of 13C-labeled γ-hydroxybutyrates for EPR studies with 4-hydroxybutyryl-CoA dehydratase. Bioorganic Chemistry 2005, 33(1), 53-66.
  • Griffin RJ, Fontana G, Golding BT, Guiard SL, Hardcastle IR, Leahy JJJ, Martin N, Richardson C, Rigoreau LJM, Stockley ML, Smith GCM. Selective benzopyranone and pyrimido[2,1-alpha]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. Journal of Medicinal Chemistry 2005, 48(2), 569-585.
  • Pierik AJ, Ciceri D, Lopez RF, Kroll F, Broker G, Beatrix B, Buckel W, Golding BT. Searching for intermediates in the carbon skeleton rearrangement of 2-methyleneglutarate to (R)-3-methylitaconate catalyzed by coenzyme B 12-dependent 2-methyleneglutarate mutase from Eubacterium barkeri. Biochemistry 2005, 44(31), 10541-10551.
  • Henderson AP, Barnes ML, Bleasdale C, Cameron R, Clegg W, Heath SL, Lindstrom AB, Rappaport SM, Waidyanatha S, Watson WP, Golding BT. Reactions of benzene oxide with thiols including glutathione. Chemical Research in Toxicology 2005, 18(2), 265-270.
  • Silvari V, Haglund J, Jenssen D, Golding BT, Ehrenberg L, Tornqvist M. Reaction-kinetic parameters of glycidamide as determinants of mutagenic potency. Mutation Research - Genetic Toxicology and Environmental Mutagenesis 2005, 580(1-2), 91-101.
  • Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, Smith GCM, Martin NMB, Workman P, Raynaud FI. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. British Journal of Cancer 2005, 93(9), 1011-1018.
  • Pennati M, Campbell AJ, Curto M, Binda M, Cheng Y, Wang L, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IR, Henderson A, Zaffaroni N, Newell DR. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation. Molecular Cancer Therapeutics 2005, 4(9), 1328-1337.
  • Hardcastle I, Ahmed S, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin R, Guyenne S, Hutton C, Källblad P, Kemp S, Kitching M, Newell D, Norbedo S, Northen J, Reid R, Saravanan K, Willems H, Lunec J. Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorganic and Medicinal Chemistry Letters 2005, 15(5), 1515-1520.
  • Paulsson B, Rannug A, Henderson AP, Golding BT, Tornqvist M, Warholm M. In vitro studies of the influence of glutathione transferases and epoxide hydrolase on the detoxification of acrylamide and glycidamide in blood. Mutation Research: Genetic Toxicology and Environmental Mutagenesis 2005, 580(1-2), 53-59.
  • Barfod R, Eriksen J, Golding BT, Hammershoi A, Jacobsen TA, Langkilde A, Larsen S, Monsted O, Sargeson AM, Sorensen HO. Facile cobalt(III) template synthesis of novel branched hexadentate polyamine monocarboxylates. Dalton Transactions 2005, (3), 491-500.
  • Henderson AP, Bleasdale C, Delaney K, Lindstrom AB, Rappaport SM, Waidyanatha S, Watson WP, Golding BT. Evidence for the formation of Michael adducts from reactions of (E,E)-muconaldehyde with glutathione and other thiols. Bioorganic Chemistry 2005, 33(5), 363-373.
  • Hardcastle I, Cockcroft X, Curtin NJ, El-Murr M, Leahy JJJ, Stockley M, Golding BT, Rigoreau L, Richardson C, Smith G, Griffin RJ. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. Journal of Medicinal Chemistry 2005, 48(24), 7829-7846.
  • Begemann P, Christova-Georgieva NI, Sangaiah R, Koc H, Zhang D, Golding BT, Gold A, Swenberg JA. Synthesis, characterization, and identification of N7-guanine adducts of isoprene monoepoxides in vitro. Chemical Research in Toxicology 2004, 17(7), 929-936.
  • Scott R, Naser U, Friedrich P, Selmer T, Buckel W, Golding BT. Stereochemistry of hydrogen removal from the 'unactivated' C-3 position of 4-hydroxybutyryl-CoA catalysed by 4-hydroxybutyryl-CoA dehydratase. Chemical Communications 2004, 10(10), 1210-1211.
  • Curtin, N., Barlow, H., Bowman, K., Calvert, A. H., Davison, R., Golding, B., Huang, B., Loughlin, P., Newell, D., Smith, P., Griffin, R. Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein. Journal of Medicinal Chemistry 2004, 47(20), 4905-4922.
  • White, A., Curtin, N.J., Eastman, B., Golding, B.T., Hostomsky, Z., Kyle,S., Li, J., Maegley, K., Skalitzky, D., Webber, S., Yu, X., Griffin, R.J. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2004, 14(10), 2433-2437.
  • Castillo-Melendez JA, Golding BT. Optimisation of the synthesis of guanidines from amines via nitroguanidines using 3,5-dimethyl-N-nitro-1H-pyrazole-1-carboxamidine. Synthesis 2004, (10), 1655-1663.
  • Hardcastle IR, Arris CE, Bentley J, Boyle FT, Chen Y, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Jewsbury, P., Menyerol, J., Mesguiche, V., Newell, D.R., Noble, M., Pratt, D., Wang, L., Whitfield, H.J. N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2. Journal of Medicinal Chemistry 2004, 47(15), 3710-3722.
  • Scott R, Golding BT. Improved synthesis of enantiomerically pure Etomoxir and its 2,4-dinitrophenyl analogue. Arkivoc 2004, 2004(x), 118-133.
  • Leahy JJJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, Smith GCM. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorganic & Medicinal Chemistry Letters 2004, 14(24), 6083-6087.
  • Chetty R, Christensen PA, Golding BT, Scott K. Fundamental and applied studies on the electrochemical hydrodehalogenation of halogenated phenols at a palladised titanium electrode. Applied Catalysis A: General 2004, 271(1-2), 185-194.
  • Tikhe J, Webber S, Hostomsky Z, Maegley K, Ekkers A, Li J, Yu X, Almassy R, Kumpf R, Boritzki T, Zhang C, Calabrese C, Curtin NJ, Kyle S, Thomas HD, Wang L, Calvert AH, Golding B, Griffin RJ, Newell DR. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2004, 47(22), 5467-5481.
  • Speranza G, Buckel W, Golding BT. Coenzyme B12-dependent enzymatic dehydration of 1,2-diols: Simple reaction, complex mechanism!. Journal of Porphyrins and Phthalocyanines 2004, 8(1-3), 290-300.
  • Fred C, Cantillana T, Henderson AP, Golding BT, Tornqvist M. Adducts of N-terminal valines in hemoglobin with isoprene diepoxide, a metabolite of isoprene. Rapid Communications in Mass Spectrometry 2004, 18(18), 2177-2184.
  • Watson WP, Munter T, Golding BT. A new role for glutathione: Protection of vitamin B₁₂ from depletion by xenobiotics. Chemical Research in Toxicology 2004, 17(12), 1562-1567.
  • Henderson AP, Bleasdale C, Clegg W, Golding BT. 2,6-Diarylaminotetrahydropyrans from Reactions of Glutaraldehyde with Anilines: Models for Biomolecule Cross-Linking. Chemical Research in Toxicology 2004, 17(3), 378-382.
  • Skalitzky, D., Marakovits, J., Maegley, K., Ekker, A., Yu, X., Hostomsky, Z., Webber, S., Eastman, B., Almassy, R., Li, J., Curtin, N. J., Newell, D. R., Calvert, A. H., Griffin, R. J., Golding, B. T. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. Journal of Medicinal Chemistry 2003, 46(2), 210-213.
  • Sayle, K., Bentley, J., Boyle, F., Calvert, A. H., Cheng, Y., Curtin, N. J., Endicott, J., Golding, B., Hardcastle, I., Jewsbury, P., Mesguiche, V., Newell, D. R., Noble, M., Parsons, R., Pratt, D., Wang, L., Griffin, R. J. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters 2003, 13(18), 3079-3082.
  • Darley DJ, Selmer T, Clegg W, Harrington RW, Buckel W, Golding BT. Stereocontrolled Synthesis of (2R,3S)-2-Methylisocitrate, a Central Intermediate in the Methylcitrate Cycle. Helvetica Chimica Acta 2003, 86(12), 3991-3999.
  • Golding BT, Cottrell L, Mackay D, Zhang D, Watson WP. Stereochemical and kinetic comparisons of mono- and diepoxide formation in the in vitro metabolism of isoprene by liver microsomes from rats, mice, and humans. Chemical Research in Toxicology 2003, 16(7), 933-944.
  • Laval G, Golding BT. One-pot sequence for the decarboxylation of α-amino acids. Synlett 2003, (4), 542-546.
  • Hamilton JF, Lewis AC, Bloss C, Wagner V, Henderson AP, Golding BT, Wirtz K, Martin-Reviejo M, Pilling MJ. Measurements of photo-oxidation products from the reaction of a series of alkyl-benzenes with hydroxyl radicals during EXACT using comprehensive gas chromatography. ATMOSPHERIC CHEMISTRY AND PHYSICS 2003, 3, 1999-2014.
  • Paulsson B, Kotova N, Grawe J, Henderson A, Granath F, Golding B, Tornqvist M. Induction of micronuclei in mouse and rat by glycidamide, genotoxic metabolite of acrylamide. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2003, 535(1), 15-24.
  • Chetty R, Christensen PA, Golding BT. In situ FTIR studies on the electrochemical reduction of halogenated phenols. Chemical Communications 2003, 9(8), 984-985.
  • Whitfield HJ, Griffin RJ, Hardcastle IR, Henderson AP, Meneyrol J, Mesguiche V, Sayle KL, Golding BT. Facilitation of addition-elimination reactions in pyrimidines and purines using trifluoroacetic acid in trifluoroethanol. Chemical Communications 2003, (22), 2802-2803.
  • Munter T, Cottrell L, Golding BT, Watson WP. Detoxication Pathways Involving Glutathione and Epoxide Hydrolase in the in Vitro Metabolism of Chloroprene. Chemical Research in Toxicology 2003, 16(10), 1287-1297.
  • Hetzel M, Brock M, Selmer T, Pierik AJ, Golding BT, Buckel W. Acryloyl-CoA reductase from Clostridium propionicum: An enzyme complex of propionyl-CoA dehydrogenase and electron-transferring flavoprotein. European Journal of Biochemistry 2003, 270(5), 902-910.
  • Mesguiche, V, Parsons, R.J., Arris, C.E., Bentley, J., Boyle, F., Curtin, N.J., Davies, T.G., Endicott, J., Gibson, A., Golding, B., Griffin, R.J., Jewsbury, P., Johnson, L.N., Newell, D.R., Noble, M.E.M., Wang, L., Hardcastle, I.R. 4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters 2003, 13(2), 217-222.
  • Hollick JJ, Golding BT, Hardcastle IR, Martin N, Richardson C, Rigoreau LJM, Smith GCM, Griffin RJ. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorganic & Medicinal Chemistry Letters 2003, 13(18), 3083-3086.
  • Carey KA, Clegg W, Elsegood MRJ, Golding BT, Maskill H. 1,2-Bis[bis(4-methoxyphenyl)hydroxymethyl]benzene. Acta Crystallographica, Section E: Structure Reports Online 2003, E59(3), o263-o265.
  • Henderson AP, Mutlu E, Leclercq A, Bleasdale C, Clegg W, Henderson RA, Golding BT. Trapping of benzene oxide-oxepin and methyl-substituted derivatives with 4-phenyl- and 4-pentafluorophenyl-1,2,4-triazoline-3,5-dione. Chemical Communications 2002, 8(17), 1956-1957.
  • Carey KA, Clegg W, Elsegood MRJ, Golding BT, Hill MNS, Maskill H. Synthesis of highly hindered oxepins and an azepine from bis-trityl carbenium ions: structural characterisation by NMR and X-ray crystallography. Journal of the Royal Chemical Society: Perkin Transactions 1 2002, (23), 2673-2679.
  • Butler PA, Crane CG, Golding BT, Hammershoi A, Hockless DC, Petersen TB, Sargeson AM, Ware DC. Synthesis of 2-(nitromethyl)ornithine from ornithine mediated by cobalt(III). Inorganica Chimica Acta 2002, 331(1), 318-321.
  • Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology 2002, 9(10), 745-749.
  • Pierik AJ, Ciceri D, Broker G, Edwards CH, McFarlane W, Winter J, Buckel W, Golding BT. Rotation of the exo-methylene group of (R)-3-methylitaconate catalyzed by coenzyme B12-dependent 2-methyleneglutarate mutase from Eubacterium barkeri. Journal of the American Chemical Society 2002, 124(47), 14039-14048.
  • Gibson A, Arris CE, Bentley J, Boyle F, Curtin NJ, Davies T, Endicott J, Golding BT, Grant S, Griffin R, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J., Whitfield, H.J. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives. Journal of Medicinal Chemistry 2002, 45(16), 3381-3393.
  • Koch SSC, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li JK, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. Journal of Medicinal Chemistry 2002, 45(23), 4961-4974.
  • Munter T, Cottrell L, Hill S, Kronberg L, Watson WP, Golding BT. Identification of adducts derived from reactions of (1-chloroethenyl)oxirane with nucleosides and calf thymus DNA. Chemical Research in Toxicology 2002, 15(12), 1549-1560.
  • Haglund J, Henderson AP, Golding BT, Tornqvist M. Evidence for phosphate adducts in DNA from mice treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Chemical Research in Toxicology 2002, 15(6), 773-779.
  • Northen J, Boyle F, Clegg W, Curtin NJ, Edwards A, Griffin R, Golding B. Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido-[5,4-d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines. Journal of the Chemical Society. Perkin Transactions 1 2002, 2(1), 108-115.
  • Laval G, Clegg W, Crane CG, Hammershoi A, Sargeson AM, Golding BT. Assembly of polyamines via amino acids from three components using cobalt(III) template methodology. Chemical Communications 2002, 8(17), 1874-1875.
  • Huhta MS, Ciceri D, Golding BT, Marsh ENG. A novel reaction between adenosylcobalamin and 2-methyleneglutarate catalyzed by glutamate mutase. Biochemistry 2002, 41(9), 3200-3206.
  • Smith DM, Golding BT, Radom L. Understanding the mechanism of B-12-dependent diol dehydratase: A synergistic retro-push-pull proposal. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 2001, 123(8), 1664-1675.
  • Stockley M, Clegg W, Fontana G, Golding BT, Martin N, Rigoreau LJM, Smith GCM, Griffin RJ. Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035). Bioorganic & Medicinal Chemistry Letters 2001, 11(21), 2837-2841.
  • Liu JY, Ma XY, Golding BT. Study on synthesis of ethyl 3-oxo-(S)-(+)-6,7-di-O-isopropylidene-6,7-dihydroxyheptanoate. Chinese Journal of Inorganic Chemistry 2001, 21(1), 71-74.
  • Davies TG, Endicott JA, Johnson LN, Noble ME, Arris CE, Bentley J, Calvert AH, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IH, Mesguiche V, Newell H, Parsons RJ, Whitfield HJ, Boyle T, Jewsbury P. Structure based design of a potent inhibitor of cdk2. Cellular and Molecular Biology Letters 2001, 6(2B), 470.
  • Davies TG, Endicott JA, Noble ME, Johnson LN, Arris CE, Bentley J, Boyle FT, Calvert AH, Curtin NJ, Jewsberry PJ, Gibson AE, Golding BT, Griffin RJ, Hardcastle I, Mesguiche V, Parsons R, Whitfield H, Newell DR. Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design. Cellular and Molecular Biology Letters 2001, 6(2B), 514-515.
  • Wetmore SD, Smith DM, Golding BT, Radom L. Interconversion of (S)-glutamate and (2S,3S)-3-methylaspartate: A distinctive B-12-dependent carbon-skeleton rearrangement. Journal of the American Chemical Society 2001, 123(33), 7963-7972.
  • Cottrell L, Golding BT, Munter T, Watson WP. In vitro metabolism of chloroprene: Species differences, epoxide stereochemistry and a de-chlorination pathway. Chemical Research in Toxicology 2001, 14(11), 1552-1562.
  • Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clinical Cancer Research 2001, 7(7), 2105-2113.
  • Heck R, Henderson AP, Kohler B, Retey J, Golding BT. Crossed acyloin condensation of aliphatic aldehydes. European Journal of Organic Chemistry 2001, (14), 2623-2627.
  • Haglund J, Rafiq A, Ehrenberg L, Golding BT, Tornqvist M. Transalkylation of phosphotriesters using cob(I)alamin: Toward specific determination of DNA-phosphate adducts. Chemical Research in Toxicology 2000, 13(4), 253-256.
  • Zhang D, Bleasdale C, Golding BT, Watson WP. Synthesis of enantiopure isoprene epoxides from (s)-lactic acid via 'dispoke' intermediates. Chemical Communications 2000, (13), 1141-1142.
  • Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research 2000, 6, 328.
  • Ciceri D, Pierik AJ, Hartrampf G, Broker G, Speranza G, Buckel W, Cornforth SJ, Golding BT. Stereochemistry of the methyl group in (R)-3-methylitaconate derived by rearrangement of 2-methylideneglutarate catalysed by a coenzyme B12-dependent mutase. Helvetica Chimica Acta 2000, 83(9), 2550-2561.
  • Barlow, H. C., Bowman, K. J., Curtin, N. J., Calvert, A. H., Golding, B. T., Huang, B., Loughlin, P. J., Newell, D. R., Smith, P. G., Griffin, R. J. Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP). Bioorganic and Medicinal Chemistry Letters 2000, 10(6), 585-589.
  • White, A.W., Almassy, R., Calvert, A.H., Curtin, N.J., Griffin, R.J., Hostomsky, Z., Maegley, K., Newell, D.R., Srinivasan, S, Golding, B.T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2000, 43(22), 4084-4097.
  • Griffin, R. J., Arris, C. E., Bleasdale, C. , Boyle, F., Calvert, A. H., Curtin, N. J., Dalby, C., Kanugula, S., Lembicz, N., Newell, D. R., Pegg, A., Golding, B. T. Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine. Journal of Medicinal Chemistry 2000, 43(22), 4071-4083.
  • Arris CE, Boyle FT, Calvert AH, Curtin NJ, Jewsbury P, Endicott JA, Gibson AE, Golding BT, Griffin RJ, Johnson LN, Laurie A, Yu W, Newell DR, Noble MEM, Sausville E, Schultz R, Garman EF, Grant S. O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
  • Andersen RJ, Ashwell S, Garnett I, Golding BT. Intramolecular functionalisation by a methylene radical of a 1,2-diol and a vicinal amino alcohol: Models for coenzyme B12-dependent diol dehydratase and ethanolamine ammonia lyase. Journal of the Chemical Society, Perkin Transactions 1 2000, (24), 4488-4498.
  • Klotz B, Barnes I, Golding BT, Becker K-H. Atmospheric chemistry of toluene-1,2-oxide/2-methyloxepin. Physical Chemistry Chemical Physics 2000, 2(2), 227-235.
  • Wang MF, Golding BT, Potter GA. A convenient preparation of p-methoxybenzyl esters. Synthetic Communications 2000, 30(23), 4197-4204.
  • Smith DM, Golding BT, Radom L. Understanding the mechanism of B12-dependent methylmalonyl-CoA mutase: partial proton transfer in action. Journal of the American Chemical Society 1999, 121(40), 9388-9399.
  • Smith DM, Golding BT, Radom L. Toward a consistent mechanism for diol dehydratase catalyzed reactions: an application of the partial-proton-transfer concept. Journal of the American Chemical Society 1999, 121(24), 5700-5704.
  • Kitching MS, Clegg W, Elsegood MRJ, Griffin RJ, Golding BT. Synthesis of 3-alkoxy- and 3-alkylamino-2-alkyl-3-arylisoindolinones. Synlett 1999, 997-999.
  • Golding BT, Mitchinson A, Clegg W, Elsegood MRJ, Griffin RJ. Protecting-group strategies for the synthesis of N4-substituted, and N1,N8-disubstituted spermidines, exemplified by hirudonine. Journal of the Chemical Society - Perkin Transactions 1 1999, (3), 349-356.
  • Smith DM, Golding BT, Radom L. On the Mechanism of Action of Vitamin B12: Theoretical Studies of the 2-Methyleneglutarate Mutase Catalyzed Rearrangement. Journal of the American Chemical Society 1999, 121(5), 1037-1044.
  • Watson W, Golding B. Weighing up the risks. CHEMISTRY IN BRITAIN 1998, 34(7), 45-48.
  • GOLDING BT. THE B12 MYSTERY. CHEMISTRY IN BRITAIN 1990, 26(10), 950-954.
  • GOLDING BT. SYNTHESIS AND REACTIONS OF CHIRAL C-3-UNITS. CHEMISTRY & INDUSTRY 1988, (19), 617-621.
  • GOLDING BT, OSULLIVAN MC, SMITH LL. CONVENIENT ROUTES TO ALKYL-SUBSTITUTED POLYAMINES. TETRAHEDRON LETTERS 1988, 29(50), 6651-6654.

• Conference Proceedings (inc. Abstracts)

  • Bertoli A, Adhikari S, Harnor SJ, Zhao Y, Lunec J, Wedge SR, Tudhope S, Wittner A, Golding BT, Hardcastle IR, Cano C, Newell DR, Griffin RJ. Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction. In: 247th ACS National Meeting and Exposition. 2014, Dallas, TX, USA: American Chemical Society.
  • Tudhope S, Zhao Y, Wittner A, Wilmore E, Bertoli A, Adhikari S, Harnor SJ, Del Bello F, Piergentili A, Lunec J, Hardcastle IR, Griffin RJ, Golding BR, Cano C, Newell DR, Wedge SR. Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels. In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
  • Martin M, Anscombe E, Meschini E, Staunton D, Geitmann M, Danielson UH, Wang LZ, Vidal RM, Reuillon T, Golding BT, Newell DR, Wedge S, Noble MEM, Endicott JA, Griffin RJ. Identification and characterization of an irreversible inhibitor of CDK2. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
  • Myers S, Martin N, Bawn R, Blackburn T, Barrett L, Reuillon T, Golding B, Griffin R, Hammonds T, Hardcastle I, Leung H, Newell D, Rigoreau L, Wong A, Cano C. Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy. In: 26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
  • Shouksmith AE, Evans LE, Griffin RJ, Golding BT, Newell H, Miller DC, Noble MEM, Endicott JA, Tweddle D. Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex. In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
  • Lebraud H, Golding BT, Meschini E, Cano C, Anscombe E, Wang LZ, Endicott JA, Noble MEM, Newell DR, Griffin RJ. Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors. In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
  • Anil B, Blackburn E, Blackburn T, Cully S, Liu J, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lunec J, Newell DR, Revill CH, Riedinger C, Watson AF, Xu Q, Zhao Y, Hardcastle IR, Noble MEM. An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones. In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
  • Cully SJ, Blackburn TJ, Cano C, Golding BT, Griffin RJ, Lunec J, Newell D, Noble M, Zhao Y, Hardcastle IR. Regiospecific synthesis of isoindolinones as MDM2 inhibitors. In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
  • Barrett L, Rennison T, Clapham KM, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Dennis M, Finlay R, Golding BT, Hardcastle IR, Newell DR, Young G, Cano C, Griffin RJ. Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK). In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
  • Myers SM, Bawn RH, Cottyn B, Golding BT, Griffin RJ, Hammonds T, Leung H, Newell D, Rigoreau L, Wong AC, Hardcastle IR, Cano C. Hit validation of ERK5 inhibitors: Expectations and challenges. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2012, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA: AMER CHEMICAL SOC.
  • Matheson CJ, Aherne W, Bayliss R, Boxall K, Cano C, Golding BT, Hardcastle IR, Mas-Droux C, Newell DR, Wang LZ, Griffin RJ. Design and synthesis of 8-substituted purines as inhibitors of Nek2 kinase. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2012, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA: AMER CHEMICAL SOC.
  • Bawn RH, Golding BT, Griffin RJ, Hammonds T, Leung H, Newell D, Rigoreau L, Wong AC, Cano C, Hardcastle IR. Development of substituted benzothiazoles as ERK5 inhibitors. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2011, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA: AMER CHEMICAL SOC.
  • Blackburn T, Ahmed H, Coxon CR, Golding BT, Griffin RJ, Newell H, Liu J, Lu X, Lunec J, Hardcastle IR. Triarylpyrroles, dual inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions. In: EJC SUPPLEMENTS. 2010, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND: PERGAMON-ELSEVIER SCIENCE LTD.
  • Carbain B, Roche C, Endicott JA, Golding BT, Hardcastle IR, Cano C, Zhen-Wang L, Newell DR, Noble MEM, Griffin RJ. Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors. In: European Journal of Cancer Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin: Elsevier.
  • Meschini E, Endicott JA, Golding BT, Hardcastle IR, Newell DR, Noble MEM, Wang LZ, Griffin RJ. Design and synthesis of dual CDK2 and CDK7 inhibitors. In: Abstracts of Papers of the American Chemical Society. 2010, American Chemical Society.
  • Cano C, Curtin NJ, Golding BT, Haggerty K, Hardcastle IR, Hummersone M, Menear K, Richardson C, Smith GCM, Griffin RJ. Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK). In: EJC SUPPLEMENTS. 2008, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND: PERGAMON-ELSEVIER SCIENCE LTD.
  • Marchetti F, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IR, Newell DR, Wang LZ. Design and synthesis of inhibitors of cyclin-dependent kinases as potential antitumor agents. In: MOLECULAR CANCER THERAPEUTICS. 2007, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH.
  • Begemann P, Georgieva NI, Sangaiah R, Gold A, Koc H, Zhang D, Golding BT, Swenberg JA. Identification of adducts formed by the reaction of isoprene monoepoxides with 2'-deoxyadenosine. In: Toxicological Sciences: 42nd Annual Meeting of the Society of Toxicology. 2003, Salt Lake City, Utah, USA: Oxford University Press.
  • Sayle KL, Mesguishe V, Parsons RJ, Bentley J, Davies TG, Endicott JA, Noble MEM, Wang LZ, Hardcastle IR, Golding BT. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. In: European Journal of Cancer: 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics. 2002, Frankfurt, Germany: Pergamon.
  • Watson WP, Cottrell L, Zhang DP, Golding BT. Metabolism and molecular toxicology of isoprene. In: 38th European Congress of Toxicology. 2001, London, UK: Elsevier Ireland Ltd.
  • Golding BT, Watson WP. Possible mechanisms of carcinogenesis after exposure to benzene. In: 2nd International Conference on Exocyclic DNA Adducts in Mutagenesis and Carcinogenesis. 1999, Heidelberg, Germany: International Agency for Research on Cancer.
  • Radom L, Smith DM, Golding BT. B-12-mediated reactions: A theoretical examination. In: Abstracts of Papers of the American Chemical Society. 1999, American Chemical Society.
  • GOLDING BT, NASSEREDDIN IK, OSULLIVAN MC. MOLECULAR MECHANISMS IN POLYAMINE BIOCHEMISTRY. In: BIOCHEMICAL SOCIETY TRANSACTIONS. 1990.

• Editorial

  • Golding BT. Academic medicinal chemistry: no country for young men (or women)?. Future Medicinal Chemistry 2015, 7(5), 549-551.

• Letter

  • Smith DM, Golding BT, Radom L. Facilitation of enzyme-catalyzed reactions by partial proton transfer: Application to coenzyme-B12-dependent methylmalonyl-CoA mutase. Journal of the American Chemical Society 1999, 121(6), 1383-1384.

• Notes

  • Golding BT. The impact of Brexit on British science: Also Sprach Zunderland. Future Medicinal Chemistry 2017, 9(3), 271-273.
  • Golding BT, Buckel W. Sir John Warcup Cornforth (1917-2013). Angewandte Chemie International Edition 2014, 53(14), 3546-3546.

• Patents

  • Chessari G, Howard S, Buck IM, Cons BD, Johnson CN, Holvey RS, Rees DC, StDenis JD, Tamanini E, Golding BT, Hardcastle IR, Cano CF, Miller DC, Noble MEM, Osborne JD, Peach J, Lewis A, Hirst KL, Whittaker BP, Watson DW, Mitchell DR, Griffin RJ. Preparation of isoindolinones as inhibitors of the MDM2-​p53 interaction having anticancer activity;WO 2017055860. WO2017055860, 2017.
  • Chessari G, Howard S, Buck IM, Cons BD, Johnson CN, Holvey RS, Rees DC, StDenis JD, Tamanini E, Golding BT, Hardcastle IR, Cano CF, Miller DC, Noble MEM, Osborne JD, Peach J, Lewis A, Hirst KL, Whittaker BP, Watson DW, Mitchell DR, Griffin RJ. Preparation of isoindolinones as inhibitors of the MDM2-​p53 interaction having anticancer activity. WO/2017055859, 06/04/2017.
  • Chessari G, Howard S, Buck IM, Cons BD, Johnson CN, Holvey RS, Rees DC, St Denis JD, Tamanini E, Golding BT, Hardcastle IR, Cano CF, Miller DC, Noble MEM, Griffin RJ, Osborne JD, Peach J, Lewis A, Hirst KL, Whittaker BP, Watson DR. ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY. PCT/GB2016/053041, 06/04/2017.
  • Reuillon T, Miller D, Myers S, Molyneux L, Cano C, Hardcastle I, Griffin R, Rigoreau L, Golding B, Noble M. Pyrrolcarboxamide Derivatives for the Inhibition of ERK5. WO/2016/042341, 24/03/2016.

• Reviews

  • Heider J, Szaleniec M, Martins BM, Seyhan D, Buckel W, Golding BT. Structure and Function of Benzylsuccinate Synthase and Related Fumarate-Adding Glycyl Radical Enzymes. Journal of Molecular Microbiology and Biotechnology 2016, 26(1-3), 29-44.
  • Selvaraj B, Buckel W, Golding BT, Ullmann GM, Martins BM. Structure and Function of 4-Hydroxyphenylacetate Decarboxylase and Its Cognate Activating Enzyme. Journal of Molecular Microbiology and Biotechnology 2016, 26(1-3), 76-91.
  • Wilkes H, Buckel W, Golding BT, Rabus R. Metabolism of Hydrocarbons in n-Alkane-Utilizing Anaerobic Bacteria. Journal of Molecular Microbiology and Biotechnology 2016, 26(1-3), 138-151.
  • Ferreri C, Golding BT, Jahn U, Ravanat JL. COST Action CM1201 "Biomimetic Radical Chemistry": free radical chemistry successfully meets many disciplines. Free Radical Research 2016, 50(Suppl. 1), S112-S128.
  • Zhang B, Golding BT, Hardcastle IR. Small-molecule MDM2-p53 inhibitors: recent advances. Future Medicinal Chemistry 2015, 7(5), 631-645.
  • Buckel W, Golding BT. Radical enzymes in anaerobes. Annual Review of Microbiology 2006, 60, 27-49.
  • Buckel W, Martins BM, Messerschmidt A, Golding BT. Radical-mediated dehydration reactions in anaerobic bacteria. Biological Chemistry 2005, 386(10), 951-959.
  • Hardcastle IR, Golding BT, Griffin RJ. Designing inhibitors of cyclin-dependent kinases. Annual Review of Pharmacology and Toxicology 2002, 42, 325-348.